CAJ | 학술논문

目的探讨在利妥昔单抗时代,滤泡性淋巴瘤国际预后指数(FLIPI)及FLIPI2在中国人群滤泡性淋巴瘤(FL)预后中的作用.方法对2003年1月至2010年12月以利妥昔单抗联合CHOP(环磷酰胺、多柔比星、长春新碱及泼尼松)样化疗方案为起始治疗的63例初治FL患者进行回顾性分析,并对所有患者进行FLIPI及FLIPI2评分.结果根据FLIPI评分,低危(评分0～1分)31例(49.2％),中危(评分2分)24例(38.1％),高危(评分3～5分)8例(12.7％);根据FLIPI2评分,低危(评分0分)17例(27.0％),中危(评分1～2分)42例(68.3％),高危(评分3～5分)4例(4.8％).FLIPI低危、中危、高危组的有效率分别为93.5％(29/31)、91.7 ％(22/24)和75.0％(6/8)(P=0.27),2年无进展生存(PFS)率分别为85.7％、75.2％和58.8％(Log-rank=1.063,P=0.59);FLIPI2低危、中危、高危组的有效率分别为100.0％(17／17)、90.7％(39／42)和50.0％(2／4)(P=0.01),2年PFS率分别为92.9％,74.0％和33.3％(Log-rank=7.075,P=0.03).结论对使用利妥昔单抗联合CHOP样化疗方案治疗的FL患者,FLIPI2比FLIPI在PFS方面更具预后意义.
목적 탐토재리타석단항시대,려포성림파류국제예후지수(FLIPI)급FLIPI2재중국인군려포성림파류(FL)예후중적작용.방법 대2003년1월지2010년12월이리타석단항연합CHOP(배린선알、다유비성、장춘신감급발니송)양화료방안위기시치료적63례초치FL환자진행회고성분석,병대소유환자진행FLIPI급FLIPI2평분.결과 근거FLIPI평분,저위(평분0～1분)31례(49.2％),중위(평분2분)24례(38.1％),고위(평분3～5분)8례(12.7％);근거FLIPI2평분,저위(평분0분)17례(27.0％),중위(평분1～2분)42례(68.3％),고위(평분3～5분)4례(4.8％).FLIPI저위、중위、고위조적유효솔분별위93.5％(29/31)、91.7 ％(22/24)화75.0％(6/8)(P=0.27),2년무진전생존(PFS)솔분별위85.7％、75.2％화58.8％(Log-rank=1.063,P=0.59);FLIPI2저위、중위、고위조적유효솔분별위100.0％(17／17)、90.7％(39／42)화50.0％(2／4)(P=0.01),2년PFS솔분별위92.9％,74.0％화33.3％(Log-rank=7.075,P=0.03).결론 대사용리타석단항연합CHOP양화료방안치료적FL환자,FLIPI2비FLIPI재PFS방면경구예후의의.
Objective To investigate the prognostic significance of follicular lymphoma international prognostic index (FLIPI) and FLIPI2 in Chinese FL patients for better prognostic model.Methods 63 newly diagnosed FL patients who received rituximab plus CHOP (cyclophosphamide,doxorubicin,vincristine and prednisone)-like chemotherapy from January 2003 to December 2010 were retrospectively analyzed according to FLIPI and FLIPI2 scoring system.Results According to FLIPI,31 patients (49.2 ％) were stratified into the low risk group (0-1 point),24 (38.1％) into the intermediate risk group (2 points),and 8 (12.7 ％) into the high risk group (3-5 points).As for FLIPI2 scoring,17 cases (27.0 ％) were classified in low risk group (0 point),42 cases (68.3 ％) in intermediate risk group (1-2 points),and 4 cases in high risk group (3-5 points).The overall response rates and 2-year progression free survival (PFS) rates of the three risk groups were 93.5 ％ (29/31),91.7 ％ (22/24),75.0 ％ (6/8) (P =0.27),and 85.7 ％,75.2 ％,58.8 ％ (Log-rank =1.063,P =0.59) respectively in FLIPI.In terms of FLIPI2,the overall response rates and 2-year PFS rates of the three groups were 100.0 ％ (17/17),90.7 ％ (39/42),50.0 ％ (2/4) (P =0.01) and 92.9 ％,74.0 ％,33.3 ％ (Log-rank =7.075,P =0.03).Conclusion FLIPI2 presents more robust prognostic significance than FLIPI in disease progression perspective for FL patients treated with R-CHOP like regimens in this study.